Nurix Therapeutics, Inc. PE Ratio
The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- Nurix Therapeutics, Inc. pe ratio for the quarter ending 2026-05-31 was -5.39, a change of -1.48 year-over-year.
- Nurix Therapeutics, Inc. pe ratio for the quarter ending 2026-02-28 was -5.6.
- Nurix Therapeutics, Inc. pe ratio for the quarter ending 2025-11-30 was -6.81.
- Nurix Therapeutics, Inc. pe ratio for the quarter ending 2025-08-31 was -2.93.
- Nurix Therapeutics, Inc. pe ratio for fiscal 2026 was -5.39.
- Nurix Therapeutics, Inc. pe ratio for fiscal 2025 was -6.81.
- Available history
- 2025-05-31 to 2026-05-31
- Data captured
Historical PE Ratio
Annual PE Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |